Post-Graduate course (PG2)

HCV Infection: The New Metabolic Frontier

Saturday July 1st 2006, 8:00 to 13:00

Organizers: L. Serfaty (France), V. Ratziu (France)

8:00
Introduction and Objectives (Lawrence Serfaty, France)

Session 1: Impact of HCV infection on lipid and glucose metabolism
Chairs: Raoul Poupon (France), Amadeo Lonardo (Italy)

8:05
Insulin resistance : clinical relevance and molecular mechanisms (Jacqueline Capeau,France)

8:20
Does HCV alter insulin signalling? (David Brenner,USA)

8:35
Interactions between HCV and lipid metabolism (Francesco Negro, Switzerland)

8:50
Acquired hypobetalipoproteinemia in chronic HCV infection (Patrice André, France)

9:00
Discussion

9:15
Epidemiology of steatosis in chronic HCV infection (Lawrence Serfaty, France)

9:30
HCV infection and diabetes: association by chance or by design? (Hashem El Serag, USA)

9:45
Controversy in physiology. Insulin resistance: how important is the liver?
- Marginal role (Jacqueline Capeau, France)
- Major importance (Vlad Ratziu, France)

10:05
Discussion

Coffee Break

Session 2: Impact of insulin resistance and steatosis on the natural history of chronic hepatitis C
Chairs: Jenny Heathcote (Canada), Lawrence Serfaty (France)

10:45
How does fat trigger fibrogenesis? (Scott Friedman, USA)

11:00
Steatosis, insulin resistance and fibrosis progression (Vlad Ratziu, France)

11:15
Determinants and consequences of steatosis in HIV-HCV coinfection (Stanislas Pol, France)

11:30
Controversy in pathology. Can the pathologist diagnose NASH in chronic hepatitis C?
- Yes: Elisabeth Powell (Australia)
- No: Pierre Bedossa (France)

11:50
Discussion

Session 3: Insulin resistance, steatosis and chronic hepatitis C : therapeutic implications
Chairs: Thierry Poynard (France), Vlad Ratziu (France)

12:00
Insulin resistance and interferon signalling (Isabelle Leclercq, Belgium)

12:15
Impact of insulin resistance and steatosis on sustained virological response (Jenny Heathcote, Canada)

12:30
Beyond antivirals: management of metabolic risk factors in HCV patients (Elisabeth Powell, Australia)

12:45
Controversy in management. Should diabetic patients be screened for HCV?
- Yes: Hashem El Serag (USA)
- No: Amedeo Lonardo (Italy)

13:00
Closing remarks: Perspectives in hepatology and diabetology (Vlad Ratziu, France)

13:00 Lunch